617 related articles for article (PubMed ID: 32791115)
1. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
Lang S; Schnabl B
Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
Bluemel S; Williams B; Knight R; Schnabl B
Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1018-G1036. PubMed ID: 27686615
[TBL] [Abstract][Full Text] [Related]
3. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
4. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
Betrapally NS; Gillevet PM; Bajaj JS
Gastroenterology; 2016 Jun; 150(8):1745-1755.e3. PubMed ID: 26948887
[TBL] [Abstract][Full Text] [Related]
5. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
9. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics.
Meng X; Li S; Li Y; Gan RY; Li HB
Nutrients; 2018 Oct; 10(10):. PubMed ID: 30297615
[TBL] [Abstract][Full Text] [Related]
11. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial proteins: intestinal guards to protect against liver disease.
Hendrikx T; Schnabl B
J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
[TBL] [Abstract][Full Text] [Related]
13. [Intestinal bacteria involved in nutritional liver disease killed by phagotherapy: a new therapeutic target].
Ciocan D; Cassard AM
Med Sci (Paris); 2020 Apr; 36(4):310-312. PubMed ID: 32356701
[No Abstract] [Full Text] [Related]
14. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
[TBL] [Abstract][Full Text] [Related]
15. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota and pediatric obesity/non-alcoholic fatty liver disease.
Yang YJ; Ni YH
J Formos Med Assoc; 2019 Mar; 118 Suppl 1():S55-S61. PubMed ID: 30509561
[TBL] [Abstract][Full Text] [Related]
17. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
[TBL] [Abstract][Full Text] [Related]
18. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
19. Microbiota, Liver Diseases, and Alcohol.
Cassard AM; Gérard P; Perlemuter G
Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
[TBL] [Abstract][Full Text] [Related]
20. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
